Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Ipsen, Galderma Expand Neurotoxin Partnership

July 11, 2014 3:16 pm | News | Comments

Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on dermatology and skin health, announced that they have significantly expanded the scope of their neurotoxin partnership. Read more...   

TOPICS:

New Compound Treats Blindness, Diabetes in Mice

July 11, 2014 3:03 pm | News | Comments

In a new study, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes. Read more...      

TOPICS:

Girl Hoped to Have Been Cured of HIV Has Relapsed

July 11, 2014 2:51 pm | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

A Mississippi girl born with the AIDS virus and in remission for more than two years despite stopping treatment now shows signs that she still harbors HIV- and therefore is not cured. Read more...                

TOPICS:
Advertisement

Sanofi Dengue Shot Offers Some Protection

July 11, 2014 2:45 pm | by Maria Cheng, AP Medical Writer | News | Comments

The most advanced vaccine for dengue only offers modest protection but could still help millions of people avoid the devastating effects of the disease known as "breakbone fever," according to a large trial. Read more...         

TOPICS:

Compounding Pharmacy Oversight Changes Signed

July 11, 2014 2:38 pm | News | Comments

Two years after a deadly nationwide meningitis outbreak linked to a compounding pharmacy in Massachusetts, Gov. Deval Patrick on Thursday signed a law he said would address a "gray area" between state and federal oversight of the pharmacies. Read more...

TOPICS:

ACS to Publish Chemistry-Focused ID Research

July 11, 2014 11:28 am | News | Comments

The ACS announced Courtney Aldrich, Ph.D., will be the editor-in-chief of the brand-new, web-only journal ACS Infectious Diseases, which will meet a growing demand for a place to publish top-notch chemistry-focused infectious diseases research, with the first issue slated for publication in January 2015. Read more...

TOPICS:

Genticel HPV Vaccine Study on Track

July 11, 2014 11:19 am | News | Comments

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announce that the enrollment of the Phase 2 RHEIA-VAC study has reached the halfway mark of its recruitment target, and the study is on track with Genticel’s initial projections. Read more...

TOPICS:

Sigma-Tau Submits EMA Application for ALL Drug

July 11, 2014 11:13 am | News | Comments

Sigma Tau Rare Disease announced the submission of an application to the European Medicines Agency (EMA) for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. Read more...

TOPICS:
Advertisement

HD Biosciences, Marshall University Partner on Drug Discovery

July 11, 2014 11:08 am | News | Comments

HD Biosciences Co. Ltd., the Marshall Institute for Interdisciplinary Research and the Marshall University Joan C. Edwards School of Medicine announced the new partnership to co-develop potential anti-cancer drugs to provide innovative medicines for unmet healthcare needs and targets. Read more...

TOPICS:

Scientists Advance Search for Novel Materials

July 11, 2014 11:00 am | News | Comments

Scientists at Stanford University and the Department of Energy’s SLAC National Accelerator Laboratory have found a way to estimate uncertainties in computer calculations that are widely used to speed the search for new materials for industry, electronics, energy, drug design and a host of other applications. Read more...

TOPICS:

Addressing Side Effects of Mainstream Treatments

July 11, 2014 10:52 am | by Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus Therapeutics Inc. | Articles | Comments

The highest-profile symptoms of major diseases are well publicized, yet for many, the side effects of mainstream therapies for these diseases can also impact physical and psychological well-being. Luckily, advances in drug delivery have offered novel treatments. Read more...

TOPICS:

JDRF, Lexicon Collaborate on Phase 2 Diabetes Trial

July 10, 2014 12:00 pm | News | Comments

Lexicon Pharmaceuticals announced that JDRF will provide funding to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in a younger population with T1D. Read more...   

TOPICS:

Vaccine Achieves Simultaneous Protection Against Ricin, Anthrax

July 10, 2014 12:00 pm | News | Comments

Soligenix Inc. announced that the combination of RiVax and VeloThrax induces protective immunity to both ricin toxin and anthrax toxin exposure. Read more...                           

TOPICS:

Tiny DNA Pyramids Enter Bacteria, Deliver Deadly Payload

July 10, 2014 12:00 pm | News | Comments

Bacterial infections usually announce themselves with pain and fever but often can be defeated with antibiotics— and then there are those that are sneaky and hard to beat. Now, scientists have built a new weapon against such pathogens in the form of tiny DNA pyramids. Read more...

TOPICS:

NIH Launches Phase 1 Trial of Novel C. Diff Drug

July 10, 2014 12:00 pm | News | Comments

The National Institute of Allergy and Infectious Diseases has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. Read more...     

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading